BeyondSpring Pharmaceuticals is a clinical-stage oncology company developing its lead asset, Plinabulin, a first-in-class small-molecule immune modulator. The company's strategy is centered on demonstrating Plinabulin's efficacy in improving overall survival and reducing chemotherapy side effects, particularly in non-small cell lung cancer (NSCLC). With a late-stage pipeline and a leadership team experienced in oncology development, BeyondSpring aims to secure regulatory approvals and establish its therapies as new standards of care in key global markets.
Oncology
Technology Platform
First-in-class small-molecule immune modulation via GEF-H1 activation through reversible tubulin binding, promoting dendritic cell maturation and T-cell priming.
Funding History
7
Total raised:$274.2M
Series C$35MOrbiMed
IPO$69.2MUndisclosed
IPO$85MUndisclosed
Series B$20MOrbiMed
Opportunities
The primary opportunity is regulatory approval and commercialization of Plinabulin in 2L/3L NSCLC, a large market with high unmet need post-immunotherapy.
A secondary, near-term opportunity exists in the multi-billion dollar CIN prophylaxis market, where Plinabulin offers a novel, mechanism-driven alternative to G-CSFs.
The company's dual-track development in both the U.S.
and China significantly expands its potential market reach and partnership options.
Risk Factors
The company faces high regulatory risk, as its future depends on successful approval of Plinabulin based on existing Phase 3 data, which regulators may deem insufficient.
There is extreme asset concentration risk, with the entire company valuation tied to a single clinical candidate.
As a pre-revenue company, it also carries significant financing and dilution risk to fund operations through to commercialization.
Competitive Landscape
In NSCLC, Plinabulin+docetaxel will compete against other later-line regimens, including chemotherapy, targeted therapies, and newer immunotherapies. In CIN prevention, it faces entrenched competition from long-acting G-CSFs (e.g., Neulasta) and newer agents. Its differentiation lies in its novel immunomodulatory mechanism aiming for both efficacy and supportive care benefits within one molecule.
